PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Journal of Clinical Pharmacy and Therapeutics

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Journal of Clinical Pharmacy and Therapeutics has 1 tracked paper indexed in Blossom (2019) from 6 authors, most often covering Ketamine, across Adolescents, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Published Papers

Paywallindividual

Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement

This case study (2019) explores repeated intravenous (IV) ketamine in synergy with antidepressants to treat refractory depression (TRD). It found that high-dose IV ketamine may stably enhance depressive symptoms and cognitive function in patients with TRD who do not tend to respond to a rapid intravenous dose of standard-dose ketamine.

Published
August 30, 2019
Journal
Journal of Clinical Pharmacy and Therapeutics
Authors
Wang, L., Wang, M., Xiong, Z., Yang, Y., Li, Z., Su, B.

Quick Facts

Papers Indexed
1
h-Index
85
Open Access
No
Publisher
Wiley
Country
United Kingdom
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.